What is the recommended dosage of libtayo? Cemiplimab is the first immunotherapy approved for adjuvant treatment in cscc, offering a new option for patients at high risk of recurrence. Regeneron pharmaceuticals) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (cscc) who are at a high risk of recurrence following surgery and radiation. 1 libtayo was reviewed by fda under priority review, a method reserved for medicines representing a potential improvement in efficacy or safety in treatments of. The fda evaluated libtayo under priority review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in the treatment of serious conditions.
WATCH
